Your browser doesn't support javascript.
loading
LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications.
Han, Yoo Jane; Boatman, Sonja M; Zhang, Jing; Du, Xinxin C; Yeh, Albert C; Zheng, Yonglan; Mueller, Jeffrey; Olopade, Olufunmilayo I.
Afiliação
  • Han YJ; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA. yjhan@medicine.bsd.uchicago.edu.
  • Boatman SM; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
  • Zhang J; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
  • Du XC; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
  • Yeh AC; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
  • Zheng Y; Fred Hutch Cancer Center, University of Washington, Seattle, WA, 98109, USA.
  • Mueller J; Center for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
  • Olopade OI; Department of Pathology, University of Chicago, Chicago, IL, 60637, USA.
Sci Rep ; 8(1): 15572, 2018 10 22.
Article em En | MEDLINE | ID: mdl-30349062
ABSTRACT
Long-noncoding RNAs (lncRNAs) have been shown to participate in oncogenesis across a variety of cancers and may represent novel therapeutic targets. However, little is known about the role of lncRNAs in basal-like breast cancer (BLBC), the aggressive form of breast cancer with no molecularly defined therapeutic target. To examine whether altered lncRNA expression contributes to the aggressive phenotype characteristic of BLBC, we performed a comparative analysis of BLBC versus non-BLBC using microarray profiling and RNA sequencing of primary breast cancer. We identified RP11-19E11.1 as a significantly up-regulated lncRNA in BLBC tumors and named it Basal-Like breast cancer Associated Transcript 1 (BLAT1). Analysis of pan-cancer datasets showed the highest expression of BLAT1 in BLBC tumors compared to all other cancers. Depletion of BLAT1 in breast cancer cells led to significantly increased apoptosis, partly because of accumulation of DNA damage. Mechanistically, BLAT1 expression is regulated at the epigenetic level via DNA methylation at CpG islands in the promoter. Concordantly, patients harboring tumors with BLAT1 hypomethylation showed decreased overall survival. Our results suggest that increased expression of BLAT1 via CpG site hypomethylation may contribute to the aggressive phenotype of BLBC, raising a possibility of new biomarkers for prognosis of aggressive BLBC tumors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação para Cima / Neoplasia de Células Basais / Epigênese Genética / RNA Longo não Codificante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação para Cima / Neoplasia de Células Basais / Epigênese Genética / RNA Longo não Codificante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article